Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma: Laboratory investigation

Journal of Neurosurgery

Volumn 120, Issue 2, 2014, Pages 331-336

  Davies, Jason M ^a   Robinson, Aaron E ^a,b   Cowdrey, Cynthia ^a,b   Mummaneni, Praveen V ^a   Ducker, Gregory S ^a   Shokat, Kevan M ^a   Bollen, Andrew ^a,b   Hann, Byron ^c   Phillips, Joanna J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chordoma xenograft; mTOR; Oncology; Phosphoproteome; SF8894

Indexed keywords

IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MLN 0128; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHORDOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NOD SCID GAMMA MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; TUMOR RECURRENCE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CHORDOMA; DISEASE MODELS, ANIMAL; EPITOPES; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED NOD; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORUS; PROTEOME; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84893251546     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2013.10.JNS13598     Document Type: Article

References (35)

1. Börgel J, Olschewski H, Reuter T, Miterski B, Epplen JT: Does the tuberous sclerosis complex include clivus chordoma? A case report. Eur J Pediatr 160:138, 2001 (Pubitemid 32204545)
2. Catton C, O'Sullivan B, Bell R, Laperriere N, Cummings B, Fornasier V, et al: Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 41:67-72, 1996
3. DeComas AM, Penfornis P, Harris MR, Meyer MS, Pochampally RR: Derivation and characterization of an extra-axial chordoma cell line (EACH-1) from a scapular tumor. J Bone Joint Surg Am 92:1231-1240, 2010
4. Diaz RJ, Guduk M, Romagnuolo R, Smith CA, Northcott P, Shih D, et al: High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis. Neoplasia 14:788-798, 2012
5. Fasig JH, Dupont WD, LaFleur BJ, Olson SJ, Cates JM: Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma. Neuropathol Appl Neurobiol 34:95-104, 2008
6. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al: Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125-132, 2013 (Erratum in Lancet 381:116, 2013)
7. García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, et al: Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 18:2603-2612, 2012
8. Hallor KH, Staaf J, Jönsson G, Heidenblad M, Vult von Steyern F, Bauer HC, et al: Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. Br J Cancer 98:434-442, 2008 (Pubitemid 351161241)
9. Han S, Polizzano C, Nielsen GP, Hornicek FJ, Rosenberg AE, Ramesh V: Aberrant hyperactivation of akt and mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res 15:1940-1946, 2009
10. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al: The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485:55-61, 2012
11. Hsu W, Mohyeldin A, Shah SR, ap Rhys CM, Johnson LF, Sedora-Roman NI, et al: Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target. Laboratory investigation. J Neurosurg 115:760-769, 2011
12. Launay SG, Chetaille B, Medina F, Perrot D, Nazarian S, Guiramand J, et al: Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review. BMC Cancer 11:423, 2011
13. Lee-Jones L, Aligianis I, Davies PA, Puga A, Farndon PA, Stemmer-Rachamimov A, et al: Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2. Genes Chromosomes Cancer 41:80-85, 2004 (Pubitemid 38988740)
14. Liu X, Nielsen GP, Rosenberg AE, Waterman PR, Yang W, Choy E, et al: Establishment and characterization of a novel chordoma cell line: CH22. J Orthop Res 30:1666-1673, 2012
15. Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, et al: Defining the role of TORC1/2 in multiple myeloma. Blood 118:6860-6870, 2011
16. McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, Zheng S, et al: Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol 97:33-40, 2010
17. Mobley BC, McKenney JK, Bangs CD, Callahan K, Yeom KW, Schneppenheim R, et al: Loss of SMARCB1/INI1 expression in poorly differentiated chordomas. Acta Neuropathol 120:745-753, 2010
18. Mueller S, Phillips J, Onar-Thomas A, Romero E, Zheng S, Wiencke JK, et al: PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol 14:1146-1152, 2012
19. Naka T, Iwamoto Y, Shinohara N, Ushijima M, Chuman H, Tsuneyoshi M: Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol 10:832-838, 1997 (Pubitemid 27374855)
20. Ostroumov E, Hunter CJ: Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein. Spine (Phila Pa 1976) 33:2774-2780, 2008
21. Ostroumov E, Hunter CJ: The role of extracellular factors in human metastatic chordoma cell growth in vitro. Spine (Phila Pa 1976) 32:2957-2964, 2007
22. Park L, Delaney TF, Liebsch NJ, Hornicek FJ, Goldberg S, Mankin H, et al: Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 65:1514-1521, 2006 (Pubitemid 44425209)
23. Presneau N, Shalaby A, Idowu B, Gikas P, Cannon SR, Gout I, et al: Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer 100:1406-1414, 2009
24. Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, et al: Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study J Pathol 223:327-335, 2011
25. Ricci-Vitiani L, Pierconti F, Falchetti ML, Petrucci G, Maira G, De Maria R, et al: Establishing tumor cell lines from aggressive telomerase-positive chordomas of the skull base. Technical note. J Neurosurg 105:482-484, 2006 (Pubitemid 44358765)
26. Rojo F, Najera L, Lirola J, Jiménez J, Guzmán M, Sabadell MD, et al: 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 13:81-89, 2007 (Pubitemid 46121856)
27. Scheil S, Brüderlein S, Liehr T, Starke H, Herms J, Schulte M, et al: Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32:203-211, 2001 (Pubitemid 32953974)
28. Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B, et al: The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol 223:336-346, 2011
29. Siu IM, Salmasi V, Orr BA, Zhao Q, Binder ZA, Tran C, et al: Establishment and characterization of a primary human chordoma xenograft model. Laboratory investigation. J Neurosurg 116:801-809, 2012
30. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, et al: Phase II study of imatinib in advanced chordoma. J Clin Oncol 30:914-920, 2012
31. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Virdis E, Messina A, et al: Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 20:1886-1894, 2009
32. Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, et al: Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 12:6920-6928, 2006 (Pubitemid 44974484)
33. Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, Conca E, et al: Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro Oncol 12:776-789, 2010
34. Weinberger PM, Yu Z, Kowalski D, Joe J, Manger P, Psyrri A, et al: Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg 131:707-711, 2005 (Pubitemid 41186892)
35. Yang C, Hornicek FJ, Wood KB, Schwab JH, Choy E, Iafrate J, et al: Characterization and analysis of human chordoma cell lines. Spine (Phila Pa 1976) 35:1257-1264, 2010